KRT17 antibody (full length)

Catalog No. ABIN7878484

The Mouse Monoclonal anti-KRT17 antibody (Clone KRT17-4604) (ABIN7878484) specifically detects KRT17 in WB and IHC (p). The antibody is reactive with Human samples.

Quick Overview for KRT17 antibody (full length) (ABIN7878484)

Target: KRT17 (Keratin 17 (KRT17))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This KRT17 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: KRT17-4604

Product Details anti-KRT17 Antibody

Binding Specificity: full length

Purpose: Cytokeratin 17 Antibody / CK17 / Keratin 17 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human KRT17 protein was used as the immunogen for the Cytokeratin 17 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the Cytokeratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the Cytokeratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for KRT17

Target: KRT17 (Keratin 17 (KRT17))

Alternative Name: Cytokeratin 17

Background: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695